IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+8.51%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$1.13B
AUM Growth
+$1.13B
(+33%)
Cap. Flow
+$321M
Cap. Flow
% of AUM
28.43%
Top 10 Holdings %
Top 10 Hldgs %
39.2%
Holding
99
New
35
Increased
28
Reduced
13
Closed
17
Top Buys
| 1 |
Centene
CNC
|
$30.3M |
| 2 |
Cardinal Health
CAH
|
$29.6M |
| 3 |
Vera Therapeutics
VERA
|
$27.5M |
| 4 |
CVS Health
CVS
|
$22.4M |
| 5 |
Neurocrine Biosciences
NBIX
|
$21.8M |
Top Sells
| 1 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$35M |
| 2 |
Novartis
NVS
|
$23M |
| 3 |
Tenet Healthcare
THC
|
$16.4M |
| 4 |
Arcellx
ACLX
|
$13.4M |
| 5 |
Medtronic
MDT
|
$12M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Keros Therapeutics
KROS
$640M
| $7.12M | 0.61% |
450,000
+250,000
| +125% | +$3.96M |
|
52
Regenxbio
RGNX
$498M
| $6.96M | 0.59% |
900,000
-375,000
| -29% | -$2.9M |
|
53
QuidelOrtho
QDEL
$1.87B
| $6.68M | 0.57% |
150,000
+25,000
| +20% | +$1.11M |
|
54
Catalyst Pharmaceutical
CPRX
$2.42B
| $6.26M | 0.53% |
300,000
-100,000
| -25% | -$2.09M |
|
55
Viking Therapeutics
VKTX
$3.02B
| $6.04M | 0.51% |
+150,000
| New | +$6.04M |
|
56
Bruker
BRKR
$4.45B
| $5.86M | 0.5% |
100,000
-35,000
| -26% | -$2.05M |
|
57
Repligen
RGEN
$6.54B
| $5.76M | 0.49% |
+40,000
| New | +$5.76M |
|
58
Alignment Healthcare
ALHC
$3.23B
| $5.63M | 0.48% |
+500,000
| New | +$5.63M |
|
59
Illumina
ILMN
$15.2B
| $5.35M | 0.46% |
+40,000
| New | +$5.35M |
|
60
Insulet
PODD
$24.2B
| $5.22M | 0.45% |
+20,000
| New | +$5.22M |
|
61
Arrowhead Research
ARWR
$3.84B
| $5.17M | 0.44% |
+275,000
| New | +$5.17M |
|
62
Nurix Therapeutics
NRIX
$723M
| $4.71M | 0.4% |
250,000
+50,000
| +25% | +$942K |
|
|
WBA
63
DELISTED
Walgreens Boots Alliance
WBA
| $4.67M | 0.4% |
+500,000
| New | +$4.67M |
|
64
TG Therapeutics
TGTX
$5.03B
| $4.52M | 0.38% |
+150,000
| New | +$4.52M |
|
65
Pliant Therapeutics
PLRX
$105M
| $3.95M | 0.34% |
300,000
| – | – |
|
|
SWTX
66
DELISTED
SpringWorks Therapeutics
SWTX
| $3.61M | 0.31% |
+100,000
| New | +$3.61M |
|
67
Dyne Therapeutics
DYN
$1.92B
| $3.53M | 0.3% |
+150,000
| New | +$3.53M |
|
|
MREO
68
Mereo BioPharma
MREO
$275M
| $3.5M | 0.3% |
1,000,000
| – | – |
|
69
Sana Biotechnology
SANA
$759M
| $3.26M | 0.28% |
2,000,000
+200,000
| +11% | +$326K |
|
70
Zentalis Pharmaceuticals
ZNTL
$123M
| $3.18M | 0.27% |
+1,050,000
| New | +$3.18M |
|
71
Terns Pharmaceuticals
TERN
$651M
| $2.49M | 0.21% |
450,000
+150,000
| +50% | +$831K |
|
72
Rezolute
RZLT
$630M
| $2.45M | 0.21% |
500,000
+250,000
| +100% | +$1.23M |
|
73
STAAR Surgical
STAA
$1.35B
| $2.43M | 0.21% |
100,000
+50,000
| +100% | +$1.21M |
|
74
Travere Therapeutics
TVTX
$1.75B
| $1.74M | 0.15% |
+100,000
| New | +$1.74M |
|
|
SLN
75
Silence Therapeutics
SLN
$237M
| $1.38M | 0.12% |
+200,000
| New | +$1.38M |
|